(NASDAQ: LBRX) Lb Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.81%.
Lb Pharmaceuticals's earnings in 2026 is -$25,205,000.On average, 6 Wall Street analysts forecast LBRX's earnings for 2026 to be -$115,920,856, with the lowest LBRX earnings forecast at -$130,109,160, and the highest LBRX earnings forecast at -$105,379,989. On average, 5 Wall Street analysts forecast LBRX's earnings for 2027 to be -$120,308,104, with the lowest LBRX earnings forecast at -$123,926,867, and the highest LBRX earnings forecast at -$108,390,846.
In 2028, LBRX is forecast to generate -$113,386,001 in earnings, with the lowest earnings forecast at -$149,499,078 and the highest earnings forecast at -$93,336,562.